CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 31, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 23, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will...

– Phase 1 data provide rationale for sebetralstat as short-term prophylaxis for medical and dental procedures - – Patient survey data demonstrate treatment burden associated with injectable on-demand treatments for HAE - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 8, 2023--...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 2, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 27, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Apr. 12, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will...

- Enrollment in sebetralstat KONFIDENT phase 3 trial passes 50% milestone; data remains H2 2023– - Sebetralstat phase 2 data published in The Lancet – - Company funded into 2025 – CAMBRIDGE, Mass. & SALISBURY, United Kingdom --(BUSINESS WIRE)--Mar. 9, 2023-- KalVista Pharmaceuticals, Inc ....

– Orally disintegrating tablet formulation shows similar pharmacokinetics to current film-coated tablets supporting lifecycle extension in US and EU - – Real-word evidence and patient survey data demonstrate treatment burden associated with the administration of injectable on-demand treatments in...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 16, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...

- Phase 3 KONFIDENT clinical trial passes 50% enrollment milestone - - Topline data still expected in H2 2023 - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 14, 2023-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...